• 1
    Malfertheiner P, Mègraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection – the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002; 16: 16780.
  • 2
    Perri F, Qasim A, Marras L, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2003; 8(Suppl. 1):S5360.
  • 3
    Kihira K, Satoh K, Saifuku K, et al. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 10837.
  • 4
    Van der Hulst RW, Weel JF, Van der Ende A, Ten Kate FJ, Dankert J, Tytgat GN. Therapeutic options after failed Helicobacter pylori eradication therapy. Am J Gastroenterol 1996; 9: 23337.
  • 5
    Neville PM, Barrowclough S, Crocombe W, Axon AT, Wrangstadh M, Moayyedi P. Randomised study of the efficacy of omeprazole and clarithromycin with either amoxycillin or metronidazole in the eradication of Helicobacter pylori in screened primary care patients. Dig Liver Dis 2001; 33: 1314.
  • 6
    Bazzoli F, Olivieri L, De Luca L, Pozzato P, Lehours P, Megraud F. Therapy and drug resistance in Helicobacter pylori infection. Dig Liver Dis 2000; 32 (Suppl. 3): 0S20710.
  • 7
    Gisbert JP, Gisbert JL, Marcos S, Gravalos RG, Carpio D, Pajares JM. Seven-day rescue therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999; 13: 13116.
  • 8
    Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 48996.
  • 9
    Huang JQ, Hunt RH. Treatment after failure: the problem of ‘non-responders’. Gut 1999; 45(Suppl. 1):1404.
  • 10
    Gomollon F, Sicilia B, Ducons JA, Sierra E, Revillo MJ, Ferrero M. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther 2000; 14: 13358.
  • 11
    Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 133943.
  • 12
    Guslandi M. Review article: alternative antibacterial agents for Helicobacter pylori eradication. Aliment Pharmacol Ther 2001; 15: 154347.
  • 13
    Baker EN, Anderson BF, Baker HM, et al. Structure, function and flexibility of human lactoferrin. Int J Biol Macromol 1991; 13: 1229.
  • 14
    Wada T, Aiba Y, Shimizu K, Takagi A, Miwa T, Koga Y. The therapeutic effect of bovine lactoferrin in the host infected with Helicobacter pylori. Scand J Gastroenterol 1999; 34: 23843.
  • 15
    Britigan BE, Serody JS, Cohen MS. The role of lactoferrin as an anti-inflammatory molecule. Adv Exp Med Biol 1994; 335: 14356.
  • 16
    Ellison RT. The effects of lactoferrin on gram-negative bacteria. Adv Exp Med Biol 1994; 357: 7190.
  • 17
    Lonnerdal B, Lyer S. Lactoferrin: molecular structure and biological function. Annu Rev Nutr 1995; 15: 93110.
  • 18
    Levay P, Viljoen M. Lactoferrin: a general review. Haematologica 1995; 80: 25267.
  • 19
    Dial EJ, Hall LR, Serna H, Romero JJ, Fox JG, Lichtenberger LM. Antibiotic properties of bovine lactoferrin in the host infected with Helicobacter pylori. Dig Dis Sci 1998; 43: 27506.
  • 20
    Dial EJ, Lichtenberger LM. Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem Cell Biol 2002; 80: 1137.
  • 21
    Pilotto A, Rassu M, Leandro G, Franceschi M, Di Mario F. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 2000; 32: 7638.
  • 22
    Altintas E, Sezgin O, Ulu O, Aydin O, Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 2004; 10: 16568.
  • 23
    Sanchez L, Calvo M, Brock J. Biological role of lactoferrin. Arch Dis Child 1992; 67: 65761.
  • 24
    Illingworth D, Walter K, Griffiths P, Barclay R. Siderophore production and iron-regulated envelope proteins of Helicobacter pylori. Zentralbl Bakteriol 1993; 280: 1139.
  • 25
    Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417: 5525.
  • 26
    Baldwin DA, Jenny ER, Aisen P. The effect of human serum transferrin and milk lactoferrin on hydroxyl radical formation from superoxide and hydrogen peroxide. J Biol Chem 1984; 259: 133914.
  • 27
    Gutteridge JM, Paterson SK, Segal AW, Halliwell B. Inhibition of lipid peroxidation by the iron-binding protein lactoferrin. Biochem J 1981; 199: 25961.
  • 28
    Jeremy B. Lactoferrin: a multifunctional immunoregulatory protein? Immunol Today 1995; 16: 4179.
  • 29
    Mann DM, Romm E, Migliorini M. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J Biol Chem 1994; 269: 236617.
  • 30
    Zhang GH, Mann DM, Tsai CM. Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect Immun 1999; 67: 13538.
  • 31
    Cole AM, Dewan P, Ganz T. Innate antimicrobial activity of nasal secretions. Infect Immun 1999; 67: 326775.
  • 32
    Jones EM, Smart A, Bloomberg G, Burgess L, Millar MR. Lactoferrin a new antimicrobial peptide. J Appl Bacteriol 1994; 77: 20814.
  • 33
    Opekun AR, El-Zaimaity HM, Osato MS, et al. Novel therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 3542.
  • 34
    Husson MO, Legrand D, Spik G, LeClere H. Iron acquisition by Helicobacter pylori: Importance of human lactoferrin. Infect Immun 1993; 61: 26947.
  • 35
    Di Mario F, Aragona G, Dal Bó N, et al. Use of lactoferrin for Helicobacter pylori eradication: preliminary results. J Clin Gastroenterol 2003; 36: 3968.
  • 36
    Di Mario F, Aragona G, Dal Bó N, et al. Use of bovine lactoferrin for Helicobacter pylori eradication. Dig Liver Dis 2003; 35: 70610.
  • 37
    Zullo F, De Francesco V, Scaccianoce G, et al. Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicenter study. Dig Liv Dis 2005; 37: 496500.